Chinese startup Abbisko Therapeutics collaborates with Eli Lilly

China-based startup Abbisko Therapeutics has entered into a worldwide collaboration and exclusive licensing agreement with Eli Lilly and Company for the further discovery, development and potential commercialisation of novel molecules against an undisclosed target for cardiometabolic diseases with critical unmet medical needs. Under the terms of the agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform. Lilly will join the effort by providing prior discovery information associated with this target as well as certain additional disease knowledge and expertise. If Abbisko Therapeutics is successful in advancing the compounds to the agreed upon endpoints, Lilly will have the right to further develop and commercialise the opportunity. If Lilly elects not to advance the compounds, Abbisko Therapeutics will then have the right to further develop and commercialise.